Group 1 - The core point of the article is that Wanfu Biological announced the postponement and re-evaluation of the "Knowledge City Production Base Construction Project" while maintaining the original investment parameters [2] Group 2 - The decision was made during the 17th meeting of the fifth board of directors held on November 14, 2025 [2] - The board approved the re-evaluation and postponement without needing to submit the matter to the shareholders' meeting, as it falls within the board's approval authority [2] - The implementation subject, method, fundraising purpose, and investment scale of the project will not change [2]

Core Viewpoint - Wanfu Biology has decided to suspend the implementation of certain fundraising projects due to significant changes in the internal and external operating environment, aiming to avoid resource waste and reduce operational costs while maintaining long-term interests for the company and its shareholders [1][3]. Group 1 - The company held its 17th meeting of the 5th Board of Directors on November 14, where it approved the proposal to re-evaluate and suspend the implementation of certain fundraising projects [3]. - The decision to suspend the "Knowledge City Production Base Construction Project" will not change the project’s implementation subject, method, use of raised funds, or investment scale [3].

Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]

Core Viewpoint - Wanfu Biological (300482.SZ) announced the postponement and re-evaluation of the "Knowledge City Production Base Construction Project" while maintaining the original implementation subject, method, fundraising purpose, and investment scale [1] Group 1 - The fifth meeting of the board of directors approved the proposal to re-evaluate and temporarily suspend the implementation of certain fundraising projects [1] - The decision was made without changing the implementation subject, method, fundraising purpose, and investment scale of the project [1]

Core Viewpoint - Wanfu Biotech (SZ 300482) announced the convening of its 17th meeting of the 5th Board of Directors on November 14, 2025, to review documents including the proposal to re-evaluate and postpone certain fundraising projects [1] Company Summary - For the fiscal year 2024, Wanfu Biotech's revenue composition is as follows: diagnostic products account for 97.59%, while other products account for 2.41% [1] - As of the report date, Wanfu Biotech has a market capitalization of 10.3 billion yuan [1]

格隆汇11月14日丨万孚生物(300482.SZ)公布，第五届董事会第十七次会议、审议通过了《关于部分募 投项目重新论证并暂缓实施的议案》，同意公司在募投项目实施主体、实施方式、募集资金用途及投资 规模不发生变更的前提下，将"知识城生产基地建设项目"重新论证并暂缓实施。 ...

南财智讯11月14日电，万孚生物公告，公司董事会于近日收到独立董事段朝晖先生提交的书面辞职报 告，段朝晖先生因个人工作原因申请辞去公司第五届董事会独立董事职务，同时辞去董事会薪酬与考核 委员会主任委员、董事会战略委员会委员职务，其辞职后将不再担任公司任何职务。鉴于段朝晖先生的 离任将导致董事会薪酬与考核委员会中独立董事所占比例不符合相关规定，其辞职将在股东会选出新任 独立董事后生效，在此之前段朝晖先生将继续履职。公司将尽快完成独立董事的补选工作。截至公告披 露日，段朝晖先生持有公司130股股票，不存在应当履行而未履行的承诺事项。 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-068 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 第五届董事会第十七次会议决议公告 后续公司将充分考虑市场趋势及公司生产经营状况，对该募集资金投资项 目进行适时安排，同时也将密切关注行业政策及市场环境变化，确保募集资金 的有效利用和公司的持续稳定发展。 具体内容详见公司于同日在中国证监会指定创业板信息披露网站巨潮资讯 网（http://www.cninfo.com.cn）发布的《关于部分募投项目重新论证并暂缓 实施的公告》。 表决结果：同意 7 票；反对 0 票；弃权 0 票。 特此公告。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"或"本公司"）第五届 董事会第十七次会议于 2025 年 11 月 14 日上午 10:00 在公司会议室以现场与通 讯相结合的方式召开，会议通知于 2025 年 11 月 10 日以邮件、电话的方式向全 体董事发出 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 2025 年 11 月 14 日 鉴于段朝晖先生的离任将导致和薪酬与考核委员会中独立董事所占比例不 符合法律法规和公司章程的规定，根据《公司法》《深圳证券交易所上市公司自 律监管指引第 2 号—创业板上市公司规范运作》和《公司章程》的有关规定， 段朝晖先生的辞职将在股东会选出新任独立董事后生效，在此之前段朝晖先生 将继续履职。公司将尽快完成独立董事的补选工作。 截至本公告披露日，段朝晖先生持有公司 130 股股票，不存在应当履行而 未履行的承诺事项。段朝晖先生在担任公司独立董事期间独立公正、勤勉尽责， 公司董事会对段朝晖先生作出的贡献表示衷心的感谢！ 二、备查文件 独立董事的辞职报告。 特此公告。 广州万孚生物技术股份有限公司董事会 关于公司独立董事辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、独立董事离任情况 广州万孚生物技术 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-069 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于部分募投项目重新论证并暂缓实施的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市万孚生物技术股份有限公司（以下简称"公司"）于 2025 年 11 月 14 日召开第五届董事会第十七次会议、审议通过了《关于部分募投项目重新论证并 暂缓实施的议案》，同意公司在募投项目实施主体、实施方式、募集资金用途及 投资规模不发生变更的前提下，将"知识城生产基地建设项目"重新论证并暂缓 实施。保荐机构出具了核查意见，本次募投项目重新论证并暂缓实施事项在董事 会的审批权限范围内，无需提交股东会审议。现将有关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意广州万孚生物技术股份有限公司向特 定对象发行股票注册的批复》（证监许可〔2023〕1380 号）同意，公司向特定对 象发行股票 27,450,980 股，每股面值 1.00 ...